Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Medications › DPP-4 inhibitors

DPP-4 inhibitors

5 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials of DPP-4 inhibitors

3 trials tracked of DPP-4 inhibitors: 1 in phase 3 or 4 and 1 with published results. The most-cited published study has 10 citations.

3Trials tracked
1Phase 3 & 4
0Recruiting
1With published results
Phase distribution
Phase 4 1 Other / NA 2
  1. Phase 4 Efficacy in Controlling Glycaemia With Victoza® (Liraglutide) as add-on to Metformin vs. OADs as add-on to Metformin After up to 104 Weeks of Treatment in Subjects With Type 2 Diabetes Completed · 10 cited
  2. N/A Empa PASS on Urinary Tract Malignancies Completed
  3. N/A Post-authorisation Safety Study in Patients With Type 2 Diabetes to Assess the Risk of Liver Injury, Kidney Injury, Urinary Tract and Genital Infections, and Diabetic Ketoacidosis in Patients Treated With Empagliflozin, Compared to DPP-4 Inhibitors Completed

Showing the 3 most-cited and recently-updated of 3 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
GLP-1RAs show lower risk of serious liver events compared with DPP-4 inhibitors in adults with type 2 diabetes
Diabetes & Endocrinology Meta-analysis
GLP-1RAs show lower risk of serious liver events compared with DPP-4 inhibitors in adults with type 2 diabetes GLP-1 drugs may lower serious liver risks compared to DPP-4 inhibitors in type 2 diabetes
This systematic review and exploratory meta-analysis evaluated incident cirrhosis or composite serious liver events among adults with type 2…
A new analysis suggests GLP-1 receptor agonists might reduce serious liver events compared to DPP-4 inhibitors for adults with type 2 diabet…
Frontiers Jun 2, 2026
Narrative review discusses pharmacological and lifestyle interventions for type 2 diabetes and psychological health
Diabetes & Endocrinology Sys. Review
Narrative review discusses pharmacological and lifestyle interventions for type 2 diabetes and psychological health New hope for diabetes patients struggling with anxiety and depression
This narrative review examines the relationship between type 2 diabetes and conditions such as anxiety, depression, and cognitive impairment…
Diabetes drugs that control blood sugar might also help improve mood and reduce anxiety for patients living with the condition.
Frontiers Apr 30, 2026
Semaglutide linked to lower neuropsychiatric event risk vs other diabetes drugs in observational study
Diabetes & Endocrinology Cohort
Semaglutide linked to lower neuropsychiatric event risk vs other diabetes drugs in observational study Semaglutide linked to lower neuropsychiatric risk than other diabetes drugs
This observational cohort study analyzed 63,215 patients with baseline neuropsychiatric conditions across a large US federated data platform…
A large observational study suggests semaglutide may be associated with a lower risk of neuropsychiatric conditions compared to other common…
medRxiv Apr 24, 2026
Mini-review links insulin to worse COVID-19 outcomes in type 2 diabetes patients
Nephrology RCT
Mini-review links insulin to worse COVID-19 outcomes in type 2 diabetes patients Diabetes Meds Do Not Stop COVID-19
A mini-review of observational studies in patients with type 2 diabetes mellitus found that insulin was linked to worse COVID-19 outcomes, w…
Recent research proves that common diabetes pills do not protect you from getting sick or dying from a virus infection.
Frontiers Apr 15, 2026
Semaglutide dose linked to lower mortality and cardiovascular risk in patients with baseline CVD
Diabetes & Endocrinology
Semaglutide dose linked to lower mortality and cardiovascular risk in patients with baseline CVD Why Ozempic's Heart Benefits May Have Nothing to Do With Weight Loss
An observational study of 47,199 patients with baseline cardiovascular disease in a U.S.
A massive real-world study of over 47,000 heart patients suggests that semaglutide may protect the heart through direct biological effects —…
medRxiv Apr 14, 2026